FOLH1 and hepatocellular carcinoma: Notably, if PSMA PET imaging, indeed, serves as useful for HCC, we could deploy therapeutic PSMA-specific ligands either intravenously, or perhaps trans-arterially, in line with the “theranostics” approach, which employs molecular imaging to guide molecularly directed radiopharmaceutical therapy.